HCAR3 and irritable bowel syndrome: HCAR3 was also significant in active IBD and remission disease states compared to control (p = 0.025); levels of the HCAR3 ligands, 3-hydroxyoctanoic and 3-hydroxydecanoic acids were also increased (Table 1).